Literature DB >> 24831650

Population-based analysis of invasive nontypeable pneumococci reveals that most have defective capsule synthesis genes.

In Ho Park1, K Aaron Geno1, Logan K Sherwood2, Moon H Nahm3, Bernard Beall2.   

Abstract

Since nasopharyngeal carriage of pneumococcus precedes invasive pneumococcal disease, characteristics of carriage isolates could be incorrectly assumed to reflect those of invasive isolates. While most pneumococci express a capsular polysaccharide, nontypeable pneumococci are sometimes isolated. Carriage nontypeables tend to encode novel surface proteins in place of a capsular polysaccharide synthetic locus, the cps locus. In contrast, capsular polysaccharide is believed to be indispensable for invasive pneumococcal disease, and nontypeables from population-based invasive pneumococcal disease surveillance have not been extensively characterized. We received 14,328 invasive pneumococcal isolates through the Active Bacterial Core surveillance program during 2006-2009. Isolates that were nontypeable by Quellung serotyping were characterized by PCR serotyping, sequence analyses of the cps locus, and multilocus sequence typing. Eighty-eight isolates were Quellung-nontypeable (0.61%). Of these, 79 (89.8%) contained cps loci. Twenty-two nontypeables exhibited serotype 8 cps loci with defects, primarily within wchA. Six of the remaining nine isolates contained previously-described aliB homologs in place of cps loci. Multilocus sequence typing revealed that most nontypeables that lacked capsular biosynthetic genes were related to established non-encapsulated lineages. Thus, invasive pneumococcal disease caused by nontypeable pneumococcus remains rare in the United States, and while carriage nontypeables lacking cps loci are frequently isolated, such nontypeable are extremely rare in invasive pneumococcal disease. Most invasive nontypeable pneumococci possess defective cps locus genes, with an over-representation of defective serotype 8 cps variants.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24831650      PMCID: PMC4022640          DOI: 10.1371/journal.pone.0097825

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Pneumococcal infections remain a leading cause of morbidity and mortality worldwide [1]. Clinically-used pneumococcal vaccines target the capsular polysaccharide (CPS), which is considered a requirement for virulence and exceeds 94 known serotypes [2]–[6]. Since the implementation of widespread vaccination, serotypes represented in vaccines are isolated less frequently in both nasopharyngeal carriage and invasive pneumococcal disease (IPD), while certain non-vaccine serotypes are isolated more frequently [7]–[9]. Monitoring the serotype distribution of pneumococcal infections is thus vital to the prospective control and prevention of pneumococcal disease. While the majority of IPD isolates are encapsulated organisms that are serotypeable with typing antisera, nontypeable isolates (NTs) are sometimes recovered [10]–[12]. NTs may represent pneumococci that exhibit novel CPS types, have damaged or substituted capsule synthetic genes, or produce CPS below detection. NTs have been broadly categorized according to the contents of the CPS biosynthetic locus (cps), the site of genes for CPS synthesis between dexB and aliA in all known serotypes but one [2], [13]. Group I NTs retain at least partial cps loci; Group II NTs lack cps loci but in their place contain genes encoding novel proteins [10], [14]. Park, et al, further divided Group II NTs into clades [14]. Null Capsule Clade (NCC) 1 isolates contain pspK, which encodes a novel surface protein [14], [15]. NCC2 and NCC3 isolates contain aliB homologs, aliC (NCC2 only) and aliD, which encode putative lipoproteins of unknown function [10], [12], [14]. NCC isolates have been frequently described among carriage NTs [10], [12], [14]. Because nasopharyngeal carriage of pneumococcus is a prerequisite for IPD, characteristics of carriage isolates have been used to infer characteristics of IPD isolates; however, the nature of IPD NTs is unclear given the protective role of CPS, and the prevalence of IPD NTs is unknown. Rates as high as 3–4% of IPD strains have been reported to be NT based on studies of a limited number of isolates (<30) from Native American populations [11], [16], [17]. However, over 2006 and 2007, NT isolates accounted for only 0.86% of IPD cases reported to the Centers for Disease Control and Prevention through the Active Bacterial Core surveillance program [18]. The majority of characterized IPD NTs have been Group I NT [11], [12], and Scott and colleagues hypothesized that in Group I NTs with intact genetic elements (as determined by microarray), CPS is expressed below what Quellung serotyping would detect [11]. The power of studies on IPD NTs has been limited by the relative rarity of such isolates and lack of detailed sequence analyses of cps loci. From 2006 to 2009, 14,328 pneumococcal IPD isolates were recovered from 10-state population surveillance by Centers for Disease Control and Prevention (CDC) Active Bacterial Core surveillance (ABCs) and subjected to Quellung-based serotyping. Here we describe the characterization of 88 NT strains, the largest collection of IPD NTs examined to date. While the majority were Group I NT, nine Group II NT were identified and analyzed by multi-locus sequence typing (MLST) to determine their relatedness to other NT isolates. In addition, we characterized the molecular defects of the overrepresented PCR-serotype 8 (PCR-8) isolates and determined that all have mutations likely to eliminate CPS production.

Methods

Strains and Conditions

Strains were obtained by the CDC ABCs program and cultured in Todd Hewitt broth (BD Biosciences) supplemented with 0.5% yeast extract or on tryptic soy agar plates supplemented with 5% sheep's blood (BAP).

Quellung Serotyping

Serotyping was performed as previously described [19] by the (Streptococcus Laboratory or by the Minnesota Department of Public Health.

Genetic Analyses

Primers used in this study are presented in Table S1. The CDC PCR-serotyping assays have been described previously [19], [20], updates provided at www.cdc.gov/ncidod/biotech/strep/pcr.htm. One isolate was typed using a separate multiplexed PCR assay, described previously [21]. cpsA was detected using multiplex PCR assay [21] and/or in conventional PCR using primer sets cpsA-f/cpsA-r, 5202/3202, or 5694/3694. Chromosomal DNA from PCR-8 strains was initially assessed for gross defects in wchA using primer set 5114/3695, and products were sequenced with primer 5114. For extreme 3′ coverage of wchA, amplicons were generated using primer set 5830/3828 and sequenced with primer 5832. For whole cps locus sequencing, locus fragments were generated using primer sets 5825/3826, 5830/3828, 5835/3830, and 5840/3832 and sequenced using primers internal to each fragment. PCR using various combinations of primers and agarose gel electrophoresis were used to identify the region of gross defect in isolate 6265-07 prior to sequencing. Isolate 7236-07 cps locus was initially sequenced with primer set 5419/3419 and in subsequent steps by primers generated to sequences from the previous reaction. Detection of NCC genes [14], PCR for dexB/aliA [10], [14], and MLST [22], [23] were performed as previously described.

DNA Sequencing

PCR products were sequenced by the Heflin Center Genomics Core Lab, University of Alabama at Birmingham.

Statistical Analyses

Statistical analyses were performed in Microsoft Excel. Testing for overrepresentation among PCR-serotypeable NTs was performed by chi-squared analysis using expected values generated from prevalence data over the study period using an assumed sample size of 79 (i.e., the number of PCR-serotypeable isolates). Comparisons for PCR-serotypeable isolates relative to Quellung-typeable counterparts were performed by dividing the raw numbers of each group for a given serotype and confined to PCR-serotypes with two or more isolates. Serotype 8 was a statistical outlier as determined by Grubbs' test (http://graphpad.com/quickcalcs/Grubbs1.cfm) and excluded from confidence interval (CI) calculation. CI was calculated manually using standard error and the “tdist” function in Microsoft Excel.

Nucleotide Sequence Deposition

The cps locus sequence of isolate 7236-07 has been deposited at GenBank (accession number KJ363164).

Results

Some Invasive Pneumococcal Isolates are Nontypeable

During the period of 2006–2009, the CDC received 14,328 independent IPD isolates. A subset of these isolates (N = 88, 0.61%) was nontypeable by Quellung and subsequently serotyped by PCR. Seventy-nine isolates (89.8% of NT) were PCR-serotypeable or cpsA-positive and thus classified as Group I NT; their assigned serotypes, prevalence, and the prevalence of corresponding Quellung-typeable isolates are presented in Table 1. The remainder (10.2%) were Group II nontypeables. Group II NT organisms were thus extremely rare causes of IPD over this period, accounting for only 0.056% of IPD cases.
Table 1

PCR-serotype Distribution of Nontypeable Pneumococci, 2006–2009.

PCR serotype or serogroupQuellung NTs Count % total Quellung-NT (N = 88)Corresponding Quellung Serotype(s) Serotype (count); % total surveillance isolates (N = 14,328)
Group I NT
822; 25.0 8 (311); 2.17
19A8; 9.09 19A (2643); 18.4
7F/7A7; 7.95 7F (2006), 7A (1); 14.0
9N/9L6; 6.82 9N (339); 2.37
22F/22A4; 4.55 22F (1000), 22A (1); 6.99
11A/11D3; 3.41 11A (364); 2.54
16F3; 3.41 16F (405); 2.83
32; 2.27 3 (1139); 7.95
15B/15C2; 2.27 15B (145),15C (145); 2.02
19F2; 2.27 19F (148); 1.03
23B2; 2.27 23B (214); 1.49
33F/33A/372; 2.27 33F (477), 37(13), 33A (2); 3.43
342; 2.27 34 (67); 0.47
41; 1.14 4 (292); 2.04
6A1; 1.14 6A (224); 1.56
6C/6D1; 1.14 6C/6D (651); 4.54
10A1; 1.14 10A (206); 1.44
15A/15F1; 1.14 15A (408), 5F (2); 2.86
17F1; 1.14 17F (179); 1.25
18C/18B/18A/18F1; 1.14 18C (67), 18B (6), 18A (4), 18F (3); 0.56
23F1; 1.14 23F (71); 0.50
24F/24A/24B1; 1.14 24F (3), 24A (1); 0.03
311; 1.14 31 (242); 1.69
35F1; 1.14 35F (133); 0.93
cpsA + but not serotypeable by PCR3; 3.41 – (–)
Group II NT
NCC2 (aliC+ aliD+)6; 6.82
NCC4 (no ORFs)1; 1.14
Undetermined2; 2.27

Group II Nontypeable Organisms Are Generally Null Capsule Clade 2

The Group II isolates were assayed by PCR for the presence of NCC-associated genes (i.e., pspK, aliC, and aliD) [14]. No isolates exhibiting pspK (NCC1) or aliD only (NCC3) were identified; however, six isolates contained both aliC and aliD and were classified as NCC2 (Table 1). The cps locus arrangements of NCC1, NCC2, and NCC3 have been described in detail by others [10], [12], [14]. Chromosomal DNA from the remaining three isolates was subjected to PCR using primers spanning dexB and aliA [10], [14].Two of these isolates repeatedly failed to produce a product; however, isolate 7236-07 demonstrated a product ∼5 kb in length. We sequenced isolate 7236-07 through this region and determined that it contained only transposon-related elements between dexB and aliA (Fig. 1, sequence submitted to GenBank, accession no. KJ363164) and was 99% identical to the transposon elements downstream of the serotype 5 cps locus over their shared sequence (accession no. CR931637, [2]). This is the third IPD isolate to be described with only transposable elements in its cps locus [12], and we propose that NCC4 be defined as Group II NT isolates lacking non-transposon open reading frames [10], [14], [15].
Figure 1

The isolate 7236-07 cps locus does not contain capsular biosynthetic or novel surface protein genes.

Schematic of the cps locus between primers 5419 and 3419 from isolate 7236-07 (deposited to GenBank, accession no. KJ363164). Genes and spacing are to scale. dexB and aliA are truncated at their 5′ and 3′ ends, respectively, in the sequence coverage. Annotations of tnp pseudogenes were assigned corresponding to the serotype 5 cps locus (GenBank no. CR931637).

The isolate 7236-07 cps locus does not contain capsular biosynthetic or novel surface protein genes.

Schematic of the cps locus between primers 5419 and 3419 from isolate 7236-07 (deposited to GenBank, accession no. KJ363164). Genes and spacing are to scale. dexB and aliA are truncated at their 5′ and 3′ ends, respectively, in the sequence coverage. Annotations of tnp pseudogenes were assigned corresponding to the serotype 5 cps locus (GenBank no. CR931637).

Group II Nontypeables Obtained in Surveillance Are Related to Established Nontypeable Lineages

Because these Group II NT isolates were obtained from patients with IPD rather than nasopharyngeal carriage, we used MLST to assess their relatedness to previously described nontypeable lineages (Table 2). Four of these strains revealed MLST genotypes identical (ST344, ST448, and ST1186) or similar (ST1540, sharing 5 of 7 alleles with ST344) to those associated with previously-reported conjunctivitis outbreaks [24], [25]. ST1540 was previously recorded from a nontypeable carriage isolate according to the MLST database (http://www.mlst.net). Isolate 7236-07 is the first NCC4 strain to our knowledge in which sufficient residual elements remain to facilitate the identification of the likely ancestral serotype, in this case, serotype 5; consistent with this observation, the sequence type of this strain, ST4840, was associated with two serotype 5 isolates (www.mlst.net).
Table 2

Multi-locus sequence types of Group II Nontypeable Isolates, 2006–2009.

IsolateST1 Related Serotype(s)Comments
NCC2 (aliC+ aliD+)
2008236031448NTAssociated with conjunctivitis
4670-071054NTTwo-locus variant of ST344
9034-06344NTAssociated with conjunctivitis
8542-071186NTAssociated with conjunctivitis
20102161171540NT, 15Double locus variant of ST4589 (associated with NT and 9V)
20102019151540NT, 15(see above)
NCC4 (no known ORFs)
7236-0748405Serotype 5 lineage
Not Determined
8296-0613906A and 6C
20082304081917F and NTNTs represent 7 of 274 reported ST191 isolates

Data obtained from MLST.net, accessed January 26, 2014.

Data obtained from MLST.net, accessed January 26, 2014. Of the two isolates failing to produce a PCR product in the dexB/aliA region, one belonged to ST191, which has been rarely reported in association with NT organisms but is strongly associated with serotype 7F; the remaining isolate belonged to ST1390, which is associated with serotypes 6A and 6C (Table 2). Because these two isolates were cpsA-negative and share STs associated with serotypes detectable in our PCR assays, it is likely that these strains exhibit gross defects around their respective cps loci.

PCR-8 Nontypeables Are Overrepresented in Group I Nontypeables and Contain Inactivating Mutations in wchA

The serotypes identified by multiplex PCR are listed in Table 1. When compared to the prevalence of encapsulated serotype 8 isolates, PCR-8 NTs were significantly overrepresented among NT isolates (P<<0.001). Five additional NT isolates obtained in mixed culture with Quellung- serotype 8 isolates were determined to be PCR-8 and were also examined (Table 3). Identical antibiotic susceptibilities were obtained for these isolates and their Quellung counterparts, suggesting that the NTs were derived from the encapsulated isolates (data not shown).
Table 3

Mutations in PCR-serotype 8 Isolates.

IsolateMutation(s)a , b Resultc
Isolates obtained as nontypeable in pure culture
4179-08T2158G, T5050A, G5230A, G5252A, C5540TPutative promoter −10 region mutation, Wzd (D226E), Wze (T51T, A59T, P155S)
6265-07ΔA5217-A8124Wze (E57FSd), ΔwchA-wciR
2010200824G5869TWchA (E30* d)
7518-07G5875TWchA (E32*)
8286-06ΔC5900WchA (A40FS)
8199-06Tandem repeat of 5960-5968WchA (Y63*)
8390-06Insert C before C6003WchA (L75FS)
2008008783C6084AWchA (Y101*)
7631-07ΔA6232-G6619WchA (I151FS)
9164-06G6508TWchA (G243*)
8083-06C6682TWchA (R301C)
2008232774C6717GWchA (Y312*)
8158-06A6718GWchA (K313E)e
8402-06A6718GWchA (K313E)e
2008008362C6724GWchA (R315G)
7445-07ΔA6751WchA (R326FS)
2009211113C6784TWchA (Q335*)
2008008580G6833AWchA (G351D)
8174-06C6844GWchA (R355G)
7145-06A6872TWchA (Q364L)
6841-06C6920TWchA (P380L)
2008227824C6923TWchA (P381L)
Nontypeable isolates obtained in mixed culture with a Quellung-positive isolate
8992-06ΔC6194WchA (A38FS)
5238-07ΔA6690WchA (K304FS)
5241-07C6861AWchA (D360E)
2009208249C6923GWchA (P381R)
2009212775G7090AWchA (D437N)

Sequence numbers correspond to GenBank accession No. AJ239004.

Polymorphisms present in an alternative serotype 8 sequence (accession No. CR931644) were ignored.

Residue numbers correspond to amino acid sequence deduced from cap8C (Wzd), cap8D (Wze), or cap8E (WchA) in GenBank accession No. AJ239004.

FS, frameshift;

*, stop.

Residue previously identified as a site of inactivating mutation [29].

Sequence numbers correspond to GenBank accession No. AJ239004. Polymorphisms present in an alternative serotype 8 sequence (accession No. CR931644) were ignored. Residue numbers correspond to amino acid sequence deduced from cap8C (Wzd), cap8D (Wze), or cap8E (WchA) in GenBank accession No. AJ239004. FS, frameshift; *, stop. Residue previously identified as a site of inactivating mutation [29]. To investigate whether PCR-8 NTs express minor amounts of capsule, we looked for molecular defects within their cps loci. Because loss of CPS production in pneumococci frequently results from mutations in wchA [26]–[29], we amplified and sequenced wchA in these isolates (the serotype 8 cps locus is presented in Figure 2A). When compared to two serotype 8 cps locus reference sequences [2], [30], twenty-three of the twenty-seven PCR-8 strains contained single base pair changes in wchA, summarized in Table 3 and whose effects are shown in a molecular model of WchA (Figure 2B). Eleven mutations resulted in premature termination codons or frameshifts predicted to truncate WchA before amino acid 335 (Figure 2B). Twelve missense mutations were identified and were confined to the predicted C-terminal loop encoding the catalytic portion of the enzyme (Figure 2B, [31]). Isolate 8199-06 contained a short tandem duplication event, and sequencing revealed a 388-bp deletion internal to wchA of isolate 7631-07 (Table 3). The wchA mutations were likely primary, as we sequenced the entire cps locus from two isolates and found no other genetic defects than the wchA mutation. This conclusion is also supported by the findings of Melchiorre, et al., who identified mutations in wchA in two serotype 7F IPD NTs and restored CPS in those strains through overexpression of wild-type wchA [27].
Figure 2

PCR-8 nontypeable isolates contain inactivating mutations in wchA.

A. Schematic of the serotype 8 cps locus (GenBank accession No. AJ239004). Alternative nomenclature is shown for regulatory genes. B. Molecular model of WchA as predicted by TMPRED (http://www.ch.embnet.org/software/TMPRED_form.html). Black arrows indicate nonsense (*) and frameshift (**) mutations; gray arrows indicate missense mutations. Residue numbers correspond to the predicted primary amino acid sequence for WchA.

PCR-8 nontypeable isolates contain inactivating mutations in wchA.

A. Schematic of the serotype 8 cps locus (GenBank accession No. AJ239004). Alternative nomenclature is shown for regulatory genes. B. Molecular model of WchA as predicted by TMPRED (http://www.ch.embnet.org/software/TMPRED_form.html). Black arrows indicate nonsense (*) and frameshift (**) mutations; gray arrows indicate missense mutations. Residue numbers correspond to the predicted primary amino acid sequence for WchA. Because isolate 6265-07 reproducibly failed to produce a wchA product, primers outside this region were used to localize the defect, and sequencing revealed a large deletion in the cps locus spanning ∼80% of wze and all of wchA, wciQ, and wciR (Table 3, Figure 2A). The final isolate, 4179-08, exhibited no mutation in wchA despite producing no CPS as detectable by a flow cytometric serotyping assay (not shown), and its entire cps locus was sequenced. We identified five single base pair changes resulting in alterations to the putative cps gene promoter, wzd (a.k.a. cap8C, cps8C), and wze (a.k.a. cap8D, cps8D)(Table 3, Figure 2A).

Conclusions/Discussion

Although large numbers of carriage NTs have been studied, only a limited number of IPD NTs have been studied [10]–[12], [27]. Our study shows that they are isolated from patients with IPD in less than 1% of cases. Only a small fraction of IPD NTs (7 of 88) were Group II NTs (i.e., conclusively lacked cps loci) [14]. Most such isolates (6 of 7) had aliB homologs in place of the cps locus, a frequently-described finding in Group II NTs of nasopharyngeal origin [10], [12], [14]. The extremely low prevalence of these strains is not surprising when considering that the acquisition of these novel cps locus-replacing genes almost certainly arose as a fitness advantage during colonization, as invasive illness is considered a dead-end path for the organism. Indeed, the recently-identified PspK protein has been shown to increase adherence during colonization [12], [14], [15]. AliB homologs do not appear to influence adherence to epithelial cells but likely provide advantages in other facets of colonization [10]. Because their prevalence in IPD is so rare, NCC isolates may have been obtained from patients who were already immunocompromised or otherwise susceptible to infection. Consistent with previous studies, we found that the vast majority of these isolates are Group I NTs, retaining at least portions of their cps loci [11], but a striking observation is that Group I NTs tend to have serotype 8 cps loci. The observed frequency of PCR-8 among NTs vastly exceeds serotype 8 prevalence in IPD. The appearance of acapsular serotype 8 strains under continuous culture conditions using sorbarods has been described; these isolates lost CPS expression due to introduction of a tandem duplication within wchA [28]. However, we did not find a fixed pattern in wchA mutations, nor did we find any characteristic in serotype 8 wchA that should predispose it to mutation. In fact, of the other PCR serogroups/-types identified in this study with wchA genes homologous to that of serotype 8 (serotypes 6, 8, 11A, 15A, 17F, 19A, 23F, 23B, 33F, and 34) [2], [32], sharing between 93.0% and 96.5% nucleotide identity (analysis of sequences in references 2 and 30) only serotype 8 was overrepresented among IPD NTs. Only three isolates retain the potential to revert (two potential slip strand mutations and one tandem repeat [28]); however, with at longest a nine bp insertion, the expected frequency of reversion would be at most ∼10−5 [28], [33]. The even distribution between frameshift and point mutations in wchA, in addition to the observation of similar mutations found during generation of otherwise-lethal mutations in the cps locus [26], [29], suggests that these NTs are producing very little to no CPS rather than a down-regulated amount of capsule as has been hypothesized [11]. All mutations in wchA are predicted to perturb or eliminate the C-terminal catalytic domain of WchA [31]. We thus conclude that the majority of IPD NTs are defective in CPS production, frequently due to point mutations in wchA that would not be identified in superficial genetic analyses such as PCR or microarray. The inactivation of CPS expression in invasive Group I NTs is unexpected because of the protective role CPS plays for pneumococci. These isolates may thus represent an in vitro artifact and arise through an unknown mechanism during isolation and subculture in the laboratory. Although in certain serotypes (e.g., serotype 3, which exhibits mucoid colonies) nonencapsulated strains are easily distinguished from encapsulated strains on BAP, in other serotypes, the difference between a small colony and a nonencapsulated colony is not always apparent. Because it is common practice to select only one colony from a culture for Quellung analysis, the chance of inadvertently selecting a CPS-negative colony would increase the closer in size it is to the CPS-positive colony, leading to a selection bias. For serotype 3, one would expect a bias in the opposite direction, and this was what was observed: the ratio of PCR-3 isolates to Quellung-serotype 3 (0.0018) was the lowest when compared to this metric for other serotypes with at least 2 NT isolates (mean  = 0.0091; 95% CI 0.0040–0.0142). However, serotypes 34 and 9N/9L were above the CI, and their individual chi-squared values when compared to their expected prevalences (7.14 and 9.17, respectively) were unremarkable as compared to that of serotype 8 (240.05, ratio  = 0.071), so this does not appear to completely explain the abundance of PCR-8 isolates. Alternatively, one could envision a population of acapsular organisms arising during infection as the host response begins to target CPS. Under such circumstances, encapsulated organisms would be targeted by antibodies or innate lectins and rapidly opsonized with C3b through the classical or lectin pathways, depleting complement levels in a local environment to sufficiently permit transient survival of nonencapsulated organisms, which would still possess pneumococcal anti-complement enzymes (reviewed in reference [34]). This could account for the observation that NT isolates of certain serotypes are sometimes obtained in mixed culture with encapsulated isolates (LK Sherwood and B Beall, unpublished observations). Less extreme microevolutions, involving intra-serogroup changes, are known to take place. For example, in serogroups 9 and 11, one member of the serogroup (9A/11E) appears to arise independently from a different member of the serogroup (9V/11A); in both cases, the serotype switch occurs through inactivation of a single gene in the cps locus encoding an acetyl transferase, resulting in absence of an acetylated residue on the CPS repeat unit [35], [36]. Because each isolate of 9A/11E contained a different inactivating mutation, the authors concluded that these serotypes have arisen repeatedly over time during infection from strains producing the acetylated version of the CPS [35]–[37]. The low prevalence of IPD NTs could suggest underlying defects in the host patient's immunity, permitting survival of an unencapsulated population during infection. In contrast to carriage, where Group II NTs are frequently isolated [10], [12], [14], IPD NTs are composed primarily of Group I NTs with defective cps loci rather than merely reduced CPS expression. Regardless of how Group I IPD NTs arise, this finding reaffirms the essential nature of CPS in at minimum the establishment of IPD and suggests that the rare Group II IPD NT infection is likely to occur in an individual predisposed to such infections due to underlying immune defect. This finding, taken with recent work showing microevolution of CPS serotypes—likely occurring within the host during IPD [35]–[37]—suggests that caution is necessary when inferring characteristics of invasive isolates based on those determined of carriage strains. Primers used in this study. (DOCX) Click here for additional data file.
  37 in total

1.  Characterization of the type 8 capsular gene cluster of Streptococcus pneumoniae.

Authors:  R Muñoz; M Mollerach; R López; E García
Journal:  J Bacteriol       Date:  1999-10       Impact factor: 3.490

2.  A homologue of aliB is found in the capsule region of nonencapsulated Streptococcus pneumoniae.

Authors:  Lucy J Hathaway; Patricia Stutzmann Meier; Patrick Bättig; Suzanne Aebi; Kathrin Mühlemann
Journal:  J Bacteriol       Date:  2004-06       Impact factor: 3.490

3.  Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates.

Authors:  Rekha Pai; Robert E Gertz; Bernard Beall
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

4.  A community outbreak of conjunctivitis caused by nontypeable Streptococcus pneumoniae in Minnesota.

Authors:  Jessica M Buck; Catherine Lexau; Miriam Shapiro; Anita Glennen; David J Boxrud; Bonnie Koziol; Cynthia G Whitney; Bernard Beall; Richard Danila; Ruth Lynfield
Journal:  Pediatr Infect Dis J       Date:  2006-10       Impact factor: 2.129

5.  Analysis of the 5' portion of the type 19A capsule locus identifies two classes of cpsC, cpsD, and cpsE genes in Streptococcus pneumoniae.

Authors:  J K Morona; R Morona; J C Paton
Journal:  J Bacteriol       Date:  1999-06       Impact factor: 3.490

6.  Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine.

Authors:  Katherine A Poehling; Thomas R Talbot; Marie R Griffin; Allen S Craig; Cynthia G Whitney; Elizabeth Zell; Catherine A Lexau; Ann R Thomas; Lee H Harrison; Arthur L Reingold; James L Hadler; Monica M Farley; Bridget J Anderson; William Schaffner
Journal:  JAMA       Date:  2006-04-12       Impact factor: 56.272

7.  A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease.

Authors:  Mark C Enright; Brian G Spratt
Journal:  Microbiology (Reading)       Date:  1998-11       Impact factor: 2.777

8.  Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction.

Authors:  Robert E Gertz; M Catherine McEllistrem; David J Boxrud; Zhongya Li; Varja Sakota; Terry A Thompson; Richard R Facklam; John M Besser; Lee H Harrison; Cynthia G Whitney; Bernard Beall
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

9.  A single gene (tts) located outside the cap locus directs the formation of Streptococcus pneumoniae type 37 capsular polysaccharide. Type 37 pneumococci are natural, genetically binary strains.

Authors:  D Llull; R Muñoz; R López; E García
Journal:  J Exp Med       Date:  1999-07-19       Impact factor: 14.307

10.  Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes.

Authors:  Stephen D Bentley; David M Aanensen; Angeliki Mavroidi; David Saunders; Ester Rabbinowitsch; Matthew Collins; Kathy Donohoe; David Harris; Lee Murphy; Michael A Quail; Gabby Samuel; Ian C Skovsted; Margit Staum Kaltoft; Bart Barrell; Peter R Reeves; Julian Parkhill; Brian G Spratt
Journal:  PLoS Genet       Date:  2006-03-10       Impact factor: 5.917

View more
  28 in total

1.  Immunization with Pneumococcal Surface Protein K of Nonencapsulated Streptococcus pneumoniae Provides Protection in a Mouse Model of Colonization.

Authors:  Lance E Keller; Xiao Luo; Justin A Thornton; Keun-Seok Seo; Bo Youn Moon; D Ashley Robinson; Larry S McDaniel
Journal:  Clin Vaccine Immunol       Date:  2015-08-26

2.  Th17-Mediated Cross Protection against Pneumococcal Carriage by Vaccination with a Variable Antigen.

Authors:  Kirsten Kuipers; Wouter S P Jong; Christa E van der Gaast-de Jongh; Diane Houben; Fred van Opzeeland; Elles Simonetti; Saskia van Selm; Ronald de Groot; Marije I Koenders; Taj Azarian; Elder Pupo; Peter van der Ley; Jeroen D Langereis; Aldert Zomer; Joen Luirink; Marien I de Jonge
Journal:  Infect Immun       Date:  2017-09-20       Impact factor: 3.441

3.  WciG O-Acetyltransferase Functionality Differentiates Pneumococcal Serotypes 35C and 42.

Authors:  K Aaron Geno; C Allen Bush; Mengnan Wang; Cheng Jin; Moon H Nahm; Jinghua Yang
Journal:  J Clin Microbiol       Date:  2017-06-28       Impact factor: 5.948

4.  Molecular characterization of pneumococcal surface protein K, a potential pneumococcal vaccine antigen.

Authors:  A-Yeung Jang; Ho Seong Seo; Shunmei Lin; Gook-Hyun Chung; Han Wool Kim; Sangyong Lim; Lei Zhao; In Ho Park; Jae Hyang Lim; Kyung-Hyo Kim
Journal:  Virulence       Date:  2017-01-06       Impact factor: 5.882

Review 5.  Pneumococcal Capsules and Their Types: Past, Present, and Future.

Authors:  K Aaron Geno; Gwendolyn L Gilbert; Joon Young Song; Ian C Skovsted; Keith P Klugman; Christopher Jones; Helle B Konradsen; Moon H Nahm
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

6.  Mutations in pneumococcal cpsE generated via in vitro serial passaging reveal a potential mechanism of reduced encapsulation utilized by a conjunctival isolate.

Authors:  Mara G Shainheit; Michael D Valentino; Michael S Gilmore; Andrew Camilli
Journal:  J Bacteriol       Date:  2015-03-16       Impact factor: 3.490

7.  A Novel Pneumococcal Surface Protein K of Nonencapsulated Streptococcus pneumoniae Promotes Transmission among Littermates in an Infant Mouse Model with Influenza A Virus Coinfection.

Authors:  Hideki Sakatani; Masamitsu Kono; Denisa Nanushaj; Daichi Murakami; Saori Takeda; Fumie Kaneko; Moon H Nahm; Muneki Hotomi
Journal:  Infect Immun       Date:  2022-01-03       Impact factor: 3.609

8.  Streptococcus pneumoniae PspC Subgroup Prevalence in Invasive Disease and Differences in Contribution to Complement Evasion.

Authors:  Erika van der Maten; Bryan van den Broek; Marien I de Jonge; Kim J W Rensen; Marc J Eleveld; Aldert L Zomer; Amelieke J H Cremers; Gerben Ferwerda; Ronald de Groot; Jeroen D Langereis; Michiel van der Flier
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

9.  Identification and molecular epidemiology of routinely determined Streptococcus pneumoniae with negative Quellung reaction results.

Authors:  Ju Jia; Wei Shi; Fang Dong; Qingying Meng; Lin Yuan; Changhui Chen; Kaihu Yao
Journal:  J Clin Lab Anal       Date:  2022-02-16       Impact factor: 2.352

10.  Non-typeable pneumococci circulating in Portugal are of cps type NCC2 and have genomic features typical of encapsulated isolates.

Authors:  Débora A Tavares; Alexandra S Simões; Hester J Bootsma; Peter Wm Hermans; Hermínia de Lencastre; Raquel Sá-Leão
Journal:  BMC Genomics       Date:  2014-10-06       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.